9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more


Cara Therapeutics, Inc.
1 Parrot Drive
Shelton, CT 06484

Phone: 203 567 1500
Fax: 203 567 1510
Website: http://www.caratherapeutics.com

Contact(s)
Derek Chalmers - dchalmers@caratherapeutics.com

General Information

Cara Therapeutics is a clinical stage biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara’s pipeline includes drug candidates within several classes of peripherally-acting analgesics, along with a proprietary technology, GPCR DimerScreen™, for the discovery of innovative pain treatments based on novel pharmacological mechanisms

The Company’s lead drug development program encompasses peripherally-selective compounds that specifically activate kappa opioid receptors present on peripheral, pain-sensing nerves. Based on clinical studies conducted to date, and unlike currently marketed opioid receptor agonists, these new compounds have not demonstrated typical opiate side effects such as inhibition of intestinal transit (ileus), induction of life-threatening respiratory depression, or production of CNS side effects associated with euphoria or addiction.

Other Information
Ownership: Private
Parent Company: 35
World Employees: 35

Back